SCHEMBL6574363

SCHEMBL6574363

Cc1ccc(NS(=O)(=O)c2ccccc2)c(C)c1NC(=O)Cc1ccc(C#N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.47
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
RORC P51449 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 2/20 0.42
METAP2 P50579 2/20 0.42
PI4KB Q9UBF8 1/20 0.41
SLC22A12 Q96S37 1/20 0.41
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
KDM1A O60341 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ACLY P53396 1/20 0.41
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6570647 0.89 MCL1 (0.54) MCL1HDAC1HDAC8RORCALDH1A1
SCHEMBL6569935 0.83 MCL1 (0.49) MCL1HDAC1HDAC8RORCALDH1A1
SCHEMBL6574016 0.83 HDAC1 (0.51) MCL1HDAC1HDAC8RORCALDH1A1
SCHEMBL6764627 0.83 F2 (0.60) MCL1F2PRSS1PRSS2PRSS3
SCHEMBL6766536 0.82 HDAC1 (0.52) MCL1HDAC1HDAC8RORCLMNA
SCHEMBL6762133 0.82 POLB (0.53) MCL1HDAC1HDAC8RORCALDH1A1
SCHEMBL6571948 0.81 HDAC1 (0.48) MCL1HDAC1HDAC8RORCALDH1A1
SCHEMBL6765129 0.78 MGAT2 (0.56) HDAC1HDAC8RORCALDH1A1LMNA
SCHEMBL6764596 0.77 HDAC1 (0.51) MCL1HDAC1HDAC8RORCALDH1A1
SCHEMBL6767177 0.77 HDAC1 (0.51) MCL1HDAC1HDAC8RORCLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-12-09 US disclosed
EP-1414790-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-05-06 EP disclosed
WO-2003000653-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions NAT1, CYP3A5, CYP3A7 MCL1 3667/4885HDAC1 696/4885HDAC8 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.